Stockreport

BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal

BioXcel Therapeutics, Inc.  (BTAI) 
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am Check Earnings Report
PDF BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study support potenti [Read more]